In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...

Directed and produced by Morgan Neville, the Netflix documentary Breakdown: 1975 focuses on that year, in the 199th one for America, in the thick of political chicanery and cultural trauma, and in the ...

This documentary could be better, but it offers a helpful lesson for film fans new to the movies of that decade. By Alissa Wilkinson When you purchase a ticket for an independently reviewed film ...

The late release date of Morgan Neville’s Netflix documentary “Breakdown: 1975” struck me as odd. The 50th anniversary of that year will end in 2 weeks. This feature purports to be an essay on 1975 ...

Patton Oswalt, Martin Scorsese, Seth Rogen and more examine 1975 as a key cultural and historical turning point. By Daniel Fienberg Chief Television Critic Breakdown: 1975 is packed with great clips ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Top leaders from the Related ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...